ES2108228T3 - Factor de diferenciacion de megacariocitos. - Google Patents

Factor de diferenciacion de megacariocitos.

Info

Publication number
ES2108228T3
ES2108228T3 ES93305654T ES93305654T ES2108228T3 ES 2108228 T3 ES2108228 T3 ES 2108228T3 ES 93305654 T ES93305654 T ES 93305654T ES 93305654 T ES93305654 T ES 93305654T ES 2108228 T3 ES2108228 T3 ES 2108228T3
Authority
ES
Spain
Prior art keywords
differentiation factor
differentiation
megacariocitos
megacariocito
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93305654T
Other languages
English (en)
Inventor
Masafumi Tsujimoto
Fuyuki Iwasa
Nobuo Tsuruoka
Hiroshi Nakazato
Kenju Miura
Nobuhiro Ishida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2108228T3 publication Critical patent/ES2108228T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN NUEVO FACTOR DE DIFERENCIACION DE MEGACARIOCITO, POR EJEMPLO, QUE CONSISTE ESENCIALMENTE EN SEQ ID NO: 30; ADN QUE CODIFICA EL FACTOR DE DIFERENCIACION DE MEGACARIOCITO, UN VECTOR DE EXPRESION QUE COMPRENDE EL ADN, UN HUESPED TRANSFORMADO CON EL VECTOR DE EXPRESION, Y UN PROCESO PARA LA PRODUCCION DEL FACTOR DE DIFERENCIACION DE MEGACARIOCITO QUE UTILIZA EL HUESPED. EL FACTOR DE DIFERENCIACION DE MEGACARIOCITO ACELERA LA DIFERENCIACION DE MEGACARIOCITOS EN PRESENCIA DE IL-3, Y ACTUA COMO UNA TROMBOPOIETINA, Y POR CONSIGUIENTE UN MEDICAMENTE EFECTIVO PARA VARIAS ENFERMEDADES QUE CONLLEVAN UN DESCENSO DE PLAQUETAS.
ES93305654T 1992-07-17 1993-07-19 Factor de diferenciacion de megacariocitos. Expired - Lifetime ES2108228T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21230592 1992-07-17
JP6733993 1993-03-04

Publications (1)

Publication Number Publication Date
ES2108228T3 true ES2108228T3 (es) 1997-12-16

Family

ID=26408534

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93305654T Expired - Lifetime ES2108228T3 (es) 1992-07-17 1993-07-19 Factor de diferenciacion de megacariocitos.

Country Status (11)

Country Link
US (5) US5831030A (es)
EP (1) EP0583884B1 (es)
JP (1) JP3521936B2 (es)
KR (2) KR100397244B1 (es)
AU (2) AU4190893A (es)
CA (1) CA2100690C (es)
DE (1) DE69314574T2 (es)
DK (1) DK0583884T3 (es)
ES (1) ES2108228T3 (es)
HU (1) HU218411B (es)
IL (1) IL106375A0 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0775593A (ja) * 1993-09-08 1995-03-20 Suntory Ltd 蛋白質の製造方法
US8357513B1 (en) 1994-01-03 2013-01-22 Genentech, Inc. Nucleic acids encoding mpl ligand (thrombopoietin) and fragments thereof
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
DE69806003T2 (de) * 1997-03-12 2003-01-30 Pe Corp. (Ny), Foster City Dna polymerasen, die verbesserte fähigkeiten zum einbau markierter nukleotide besitzen
AU2763302A (en) * 1997-09-22 2002-05-16 Kurokawa, Kiyoshi Megsin protein
WO1999015652A1 (en) 1997-09-22 1999-04-01 Kurokawa, Kiyoshi Megsin protein
JP4567890B2 (ja) * 1999-03-19 2010-10-20 扶桑薬品工業株式会社 メグシンタンパク質の検出方法およびその用途
US7056661B2 (en) * 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
CA2385984A1 (en) * 1999-10-06 2001-04-12 Toshio Miyata Animal model for mesangial proliferative nephritis
WO2001048019A1 (fr) * 1999-12-28 2001-07-05 Kurokawa, Kiyoshi Methode permettant de diagnostiquer la nephrite proliferative a cellules mesangiales chez le rat
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
CA2436671C (en) 2000-12-05 2015-02-03 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20050042629A1 (en) 2002-09-13 2005-02-24 Applera Corporation Thermus scotoductus nucleic acid polymerases
US7052877B2 (en) 2001-11-30 2006-05-30 Applera Corporation Thermus brockianus nucleic acid polymerases
EP1613348B1 (en) * 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894440A (en) * 1986-09-17 1990-01-16 Massachusetts Institute Of Technology Method of isolating megakaryocyte stimulatory factor
IL90719A0 (en) * 1988-06-28 1990-01-18 Yissum Res Dev Co Novel nuclei acids and polypeptides encoded thereby
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production

Also Published As

Publication number Publication date
US20010026931A1 (en) 2001-10-04
AU7538796A (en) 1997-02-20
US20020164711A1 (en) 2002-11-07
AU703648B2 (en) 1999-03-25
AU4190893A (en) 1994-01-20
DK0583884T3 (da) 1998-03-16
JPH06313000A (ja) 1994-11-08
DE69314574D1 (de) 1997-11-20
HU9302059D0 (en) 1993-11-29
KR100397244B1 (ko) 2003-12-01
HUT67124A (en) 1995-02-28
IL106375A0 (en) 1993-11-15
EP0583884B1 (en) 1997-10-15
US5831030A (en) 1998-11-03
US5874253A (en) 1999-02-23
KR940005799A (ko) 1994-03-22
EP0583884A1 (en) 1994-02-23
JP3521936B2 (ja) 2004-04-26
HU218411B (hu) 2000-08-28
CA2100690A1 (en) 1994-01-18
CA2100690C (en) 2007-04-17
DE69314574T2 (de) 1998-02-19
US5972886A (en) 1999-10-26

Similar Documents

Publication Publication Date Title
ES2108228T3 (es) Factor de diferenciacion de megacariocitos.
ES2176197T3 (es) Sistema de administracion transdermal que contiene un acido acetilsalicilico para la terapia de trombosis y la profilaxis del cancer.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
ES8602121A1 (es) Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
DE58908825D1 (de) Extraktionsmittel für Poly-D(-)-3-hydroxybuttersäure.
ES2095413T3 (es) Preparacion de derivados de titanio.
ES8306325A1 (es) "proceso para la produccion microbiana de interferon fibroblasto humano".
ES2054878T3 (es) Expresion de la proapolipoproteina a-i humana.
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
ES2137182T3 (es) Derivados recombinantes del factor viii humano.
NO885275D0 (no) VaskulŸre antikoagulantproteiner, dna'er som koder for dem, fremstilling og anvendelse derav.
ES2103928T5 (es) Polipeptidos de mycobacterium y acidos nucleicos que los codifican utilizados en el diagnostico y el tratamiento de la tuberculosis.
AR247348A1 (es) Proceso para la deshidrogenacion y/o deshidrociclizacion cataliticas de hidrocarburos con dicho catalizador.
ES2191011T3 (es) Acido nucleico, vector de expresion y composiciones para la identificacion y sintesis de sialiltransferasas recombinantes.
ES2061520T3 (es) Expresion de un antigeno especifico de tumor por un virus vector recombinante y utilizacion de este para el tratamiento preventivo o curativo del tumor correspondiente.
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
ES2159403T3 (es) Poliuretanos termoplasticos que contienen principios activos.
ES2125873T3 (es) Plasmido hibrido para el antigeno con 38 kda de m. tuberculosis, e. coli como hospedante, el antigeno con 38 kda y una proteina con aproximadamente 33kda.
ATE120494T1 (de) Fibronectinbindungsprotein und dessen herstellung.
ES2168358T3 (es) Proteinas antimicrobianas de semillas de impatiens.
ES2174848T3 (es) Cepas de levadura que expresan el gen de ldh lactica, y vectores utilizables para la obtencion de las citadas cepas.
AR246310A1 (es) Procedimiento para la preparacion de la cadena alfa- del receptor de la interleucina 5 humana, o partes del mismo, secuencia del adn, vector y celula hospedante.
ES2042468T3 (es) Producto para la fijacion del cabello.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 583884

Country of ref document: ES